Louis M. Weiner - Publications

Tumor Biology Georgetown University, Washington, DC 
Cell Biology, Immunology, Molecular Biology

148 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Ajina R, Malchiodi ZX, Fitzgerald AA, Zuo A, Wang S, Moussa M, Cooper CJ, Shen Y, Johnson QR, Parks JM, Smith JC, Catalfamo M, Fertig EJ, Jablonski SA, Weiner LM. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Cancer Immunology Research. PMID 33509790 DOI: 10.1158/2326-6066.CIR-20-0272  0.48
2020 Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack. Methods in Enzymology. 636: 299-322. PMID 32178823 DOI: 10.1016/Bs.Mie.2019.06.002  0.96
2020 Wang S, Fitzgerald A, Ajina R, Jablonsk SA, Weiner LM, MacDougall J, Agarwal V, O'Neill VJ. Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis Immunology. DOI: 10.1158/1538-7445.Am2020-6636  0.48
2019 O'Connell A, Wang S, Weiner LM. Abstract A096: The potential role of fibroblast activation protein as a natural killer cell immune checkpoint Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A096  0.48
2017 Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio-Protocol. 7. PMID 29250574 DOI: 10.21769/BioProtoc.2435  0.96
2017 Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunology, Immunotherapy : Cii. PMID 29043413 DOI: 10.1007/S00262-017-2077-9  0.48
2017 Smith JP, Wang S, Weiner L, Nadella S. Abstract LB-133: De novo expression of gastrin and CCK-B receptors in cell lines derived from KPC mice Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-133  0.48
2016 Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. PMID 27546622 DOI: 10.1038/Onc.2016.288  0.96
2016 Smith JP, Wang S, Reham A, Jablonski SA, Weiner LM. Abstract 4023: Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer Cancer Research. 76: 4023-4023. DOI: 10.1158/1538-7445.Am2016-4023  0.48
2015 Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 26507197 DOI: 10.1007/S00280-015-2855-Z  0.96
2015 Parren PW, Burton DR, Bradbury A, Huston JS, Carter PJ, Veldman T, Chester KA, Larrick JW, Alfenito MR, Scott JK, Weiner LM, Adams GP, Reichert JM. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA. Mabs. 7: 981-8. PMID 26421752 DOI: 10.1080/19420862.2015.1089707  0.96
2015 Weiner LM. Cancer immunology for the clinician. Clinical Advances in Hematology & Oncology : H&O. 13: 299-306. PMID 26352774  0.96
2015 Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, ... ... Weiner LM, et al. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene. PMID 26165839 DOI: 10.1038/Onc.2015.226  0.96
2015 Redman JM, Hill EM, AlDeghaither D, Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology. PMID 25911943 DOI: 10.1016/J.Molimm.2015.04.002  0.96
2015 Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 27: 489-501. PMID 25873172 DOI: 10.1016/J.Ccell.2015.03.004  0.96
2015 von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 75: 1047-55. PMID 25791363 DOI: 10.1007/S00280-015-2705-Z  0.96
2015 AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. Journal of Clinical Pharmacology. 55: S4-20. PMID 25707963 DOI: 10.1002/Jcph.407  0.96
2015 Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, ... ... Weiner LM, et al. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene. 34: 1083-93. PMID 24662823 DOI: 10.1038/Onc.2014.51  0.96
2015 Zhang Y, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, ... ... Weiner LM, et al. Abstract 1716: Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation Cancer Research. 75: 1716-1716. DOI: 10.1158/1538-7445.Am2015-1716  0.96
2014 Larrick JW, Parren P, Huston JS, Plückthun A, Bradbury A, Tomlinson IM, Chester KA, Burton DR, Adams GP, Weiner LM, Scott JK, Alfenito MR, Veldman T, Reichert JM. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014. Mabs. 6: 1115-23. PMID 25517297 DOI: 10.4161/19420862.2014.971627  0.96
2014 Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunology Research. 2: 1186-98. PMID 25300860 DOI: 10.1158/2326-6066.Cir-14-0083  0.96
2014 Surana R, Wang S, Xu W, Jablonski SA, Weiner LM. IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunology Research. 2: 1103-12. PMID 25204776 DOI: 10.1158/2326-6066.Cir-14-0103  0.96
2014 Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. PMID 25171298 DOI: 10.1097/Coc.0000000000000118  0.96
2014 Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123: 3016-26. PMID 24652987 DOI: 10.1182/Blood-2013-10-533398  0.96
2014 Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clinical Colorectal Cancer. 13: 81-6. PMID 24512954 DOI: 10.1016/J.Clcc.2013.12.005  0.96
2014 Shivapurkar N, Weiner LM, Marshall JL, Madhavan S, Deslattes Mays A, Juhl H, Wellstein A. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. Plos One. 9: e84686. PMID 24400111 DOI: 10.1371/Journal.Pone.0084686  0.96
2014 Kim SS, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 278-91. PMID 24113515 DOI: 10.1038/Mt.2013.231  0.96
2014 Shuptrine CW, Weiner LM. Bifunctional Antibodies: Preclinical and Clinical Applications Current Cancer Research. 12: 183-211. DOI: 10.1007/978-1-4614-8809-5_10  0.96
2013 Madhavan S, Gusev Y, Natarajan TG, Song L, Bhuvaneshwar K, Gauba R, Pandey A, Haddad BR, Goerlitz D, Cheema AK, Juhl H, Kallakury B, Marshall JL, Byers SW, Weiner LM. Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Frontiers in Genetics. 4: 236. PMID 24312117 DOI: 10.3389/Fgene.2013.00236  0.96
2013 Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biotherapy & Radiopharmaceuticals. 28: 274-82. PMID 23611188 DOI: 10.1089/Cbr.2012.1329  0.96
2013 Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, ... ... Weiner LM, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discovery. 3: 96-111. PMID 23125191 DOI: 10.1158/2159-8290.Cd-12-0031  0.96
2013 Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 581-9. PMID 23104982 DOI: 10.1096/Fj.12-210377  0.96
2013 Gómez Román VR, Murray JC, Weiner LM. Antibody-Dependent Cellular Cytotoxicity (ADCC) Antibody Fc: Linking Adaptive and Innate Immunity. 1-27. DOI: 10.1016/B978-0-12-394802-1.00001-7  0.96
2012 Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecular Cancer Therapeutics. 11: 2674-84. PMID 23075808 DOI: 10.1158/1535-7163.Mct-12-0692  0.96
2012 Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA. Mabs. 4: 648-52. PMID 23007482 DOI: 10.4161/Mabs.22221  0.96
2012 Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. The New England Journal of Medicine. 366: 1156-8. PMID 22435376 DOI: 10.1056/Nejmcibr1114526  0.96
2012 Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 148: 1081-4. PMID 22424219 DOI: 10.1016/J.Cell.2012.02.034  0.96
2012 Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology. 22: 3-13. PMID 22245472 DOI: 10.1016/J.Semcancer.2011.12.009  0.96
2012 Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology, Immunotherapy : Cii. 61: 49-61. PMID 21842208 DOI: 10.1007/S00262-011-1090-7  0.96
2012 Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 31: 1217-27. PMID 21785464 DOI: 10.1038/Onc.2011.314  0.96
2011 Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, ... Weiner LM, et al. G-DOC: a systems medicine platform for personalized oncology. Neoplasia (New York, N.Y.). 13: 771-83. PMID 21969811 DOI: 10.1593/Neo.11806  0.96
2011 Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nature Reviews. Cancer. 11: 523-32. PMID 21677677 DOI: 10.1038/Nrc3081  0.96
2011 Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Research. 71: 2250-9. PMID 21406401 DOI: 10.1158/0008-5472.Can-10-2277  0.96
2011 Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. American Journal of Clinical Oncology. 34: 70-5. PMID 20458210 DOI: 10.1097/Coc.0B013E3181D2734A  0.96
2011 Murray JC, Wu CS, Weiner LM. Why cetuximab is not active in the adjuvant setting Current Colorectal Cancer Reports. 7: 211-217. DOI: 10.1007/S11888-011-0103-4  0.96
2010 Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, ... Weiner LM, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science Signaling. 3: ra67. PMID 20858866 DOI: 10.1126/Scisignal.2001083  0.96
2010 Deeken JF, Weiner LM. Supportive treatments for oncology patients: not just icing on the cake. Annals of Internal Medicine. 153: 411-2. PMID 20855805 DOI: 10.7326/0003-4819-153-6-201009210-00010  0.96
2010 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews. Immunology. 10: 317-27. PMID 20414205 DOI: 10.1038/Nri2744  0.96
2010 Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prevention Research (Philadelphia, Pa.). 3: 410-5. PMID 20332297 DOI: 10.1158/1940-6207.Capr-10-0040  0.96
2010 Wang S, Xu W, Tang Y, Surana R, Bingham C, Astsaturov IA, McCarthy K, Alpaugh RK, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Abstract LB-324: A toll-like receptor 4 agonist enhances the efficacy of trastuzumab therapy and promotes adaptive immunity and long-term protection against a human ErbB-2 (HER2)-transfected syngeneic tumor in a human HER2 transgenic mouse model Immunology. 70. DOI: 10.1158/1538-7445.Am10-Lb-324  0.96
2010 Weiner LM, Tang Y, Wang S, Surana R, Xu W, Zhou Y, Marks JD, Golemis E. Abstract PL6-2: Antibody-initiated cancer immunotherapy Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-Pl6-2  0.96
2009 Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.Ccr-09-0737  0.96
2009 Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet (London, England). 373: 1033-40. PMID 19304016 DOI: 10.1016/S0140-6736(09)60251-8  0.96
2009 Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion On Therapeutic Targets. 13: 339-62. PMID 19236156 DOI: 10.1517/14712590902735795  0.96
2008 Urtishak S, Alpaugh RK, Weiner LM, Swaby RF. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. Biomarkers in Medicine. 2: 137-45. PMID 20477435 DOI: 10.2217/17520363.2.2.137  0.96
2008 Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG. Translational Research Working Group developmental pathway for immune response modifiers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5692-9. PMID 18794077 DOI: 10.1158/1078-0432.Ccr-08-1266  0.96
2008 Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 37: 154-8. PMID 18665076 DOI: 10.1097/Mpa.0B013E31816618Ce  0.96
2008 Weiner LM. Cancer immunotherapy--the endgame begins. The New England Journal of Medicine. 358: 2664-5. PMID 18565858 DOI: 10.1056/Nejmp0803663  0.96
2008 Weiner LM. From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics. Cancer Journal (Sudbury, Mass.). 14: 147-8. PMID 18536553 DOI: 10.1097/PPO.0b013e3181772280  0.96
2008 Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. Journal of Immunology (Baltimore, Md. : 1950). 180: 6392-401. PMID 18424763 DOI: 10.4049/Jimmunol.180.9.6392  0.96
2008 Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. American Journal of Clinical Oncology. 31: 1-5. PMID 18376220 DOI: 10.1097/Coc.0B013E31805C142F  0.96
2008 Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 502-8. PMID 18223225 DOI: 10.1158/1078-0432.Ccr-07-1509  0.96
2007 Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy. 6: 1691-9. PMID 18032930 DOI: 10.4161/Cbt.6.11.4874  0.96
2007 Heimann DM, Weiner LM. Monoclonal antibodies in therapy of solid tumors. Surgical Oncology Clinics of North America. 16: 775-92, viii. PMID 18022544 DOI: 10.1016/J.Soc.2007.07.001  0.96
2007 Weiner LM. Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews. Cancer. 7: 701-6. PMID 17721434 DOI: 10.1038/Nrc2209  0.96
2007 Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. Journal of Immunology (Baltimore, Md. : 1950). 179: 2815-23. PMID 17709495 DOI: 10.4049/Jimmunol.179.5.2815  0.96
2007 Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 577-90. PMID 17667521 DOI: 10.1097/Cji.0B013E318064E7B2  0.96
2007 Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 69: 358-63. PMID 17532577 DOI: 10.1016/J.Ijrobp.2007.03.053  0.96
2007 Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 455-67. PMID 17457220 DOI: 10.1097/Cji.0B013E31803Bb421  0.96
2007 Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 109: 170-9. PMID 17154393 DOI: 10.1002/Cncr.22402  0.96
2007 Carson WE, Allen A, Weiner LM, Cheever MA, Fox BA, Keilholz U, Wigginton JM, Sondel PM, Atkins MB, Hwu P. Immunotherapy comes of age: Overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer: Los Angeles, CA, USA, 27-29 October 2006 Expert Opinion On Biological Therapy. 7: 419-422. DOI: 10.1517/14712598.7.3.419  0.96
2007 Weiner LM. Emerging concepts in monocloal antibody therapy European Journal of Cancer, Supplement. 5: 442-443. DOI: 10.1016/S1359-6349(07)70092-7  0.96
2006 Weiner LM, Borghaei H. Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Human Antibodies. 15: 103-11. PMID 17065741 DOI: 10.3233/Hab-2006-15305  0.96
2006 Movsas B, Diratzouian H, Hanlon A, Cooper H, Freedman G, Konski A, Sigurdson E, Hoffman J, Meropol NJ, Weiner LM, Coia L, Lanciano R, Stein J, Kister D, Eisenberg B. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. American Journal of Clinical Oncology. 29: 435-41. PMID 17023775 DOI: 10.1097/01.Coc.0000227480.41414.F2  0.96
2006 Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, ... ... Weiner LM, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 6: 125-32. PMID 16945168 DOI: 10.3816/Ccc.2006.N.029  0.96
2006 Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, Nakada MT. A review of antibody therapeutics and antibody-related technologies for oncology. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 351-64. PMID 16799330 DOI: 10.1097/01.Cji.0000199196.97845.C3  0.96
2006 Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. British Journal of Cancer. 94: 1621-6. PMID 16705310 DOI: 10.1038/Sj.Bjc.6603171  0.96
2006 Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1599-605. PMID 16533787 DOI: 10.1158/1078-0432.Ccr-05-2217  0.96
2006 Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Annals of Surgical Oncology. 13: 214-20. PMID 16418887 DOI: 10.1245/Aso.2006.01.001  0.96
2006 Weiner LM. Fully human therapeutic monoclonal antibodies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 1-9. PMID 16365595 DOI: 10.1097/01.Cji.0000192105.24583.83  0.96
2006 Binyamin L, Borghaei H, Weiner LM. Cancer therapy with engineered monoclonal antibodies Update On Cancer Therapeutics. 1: 147-157. DOI: 10.1016/J.Uct.2006.05.002  0.96
2005 Berger AC, Scott WJ, Freedman G, Konski A, Weiner L, Cheng JD, Goldberg M. Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer. Seminars in Oncology. 32: S16-20. PMID 16399424 DOI: 10.1053/J.Seminoncol.2005.04.017  0.96
2005 Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biotherapy & Radiopharmaceuticals. 20: 603-13. PMID 16398612 DOI: 10.1089/Cbr.2005.20.603  0.96
2005 Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clinical Colorectal Cancer. 5: S71-80. PMID 16336752 DOI: 10.3816/Ccc.2005.S.010  0.96
2005 Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 23: 1147-57. PMID 16151408 DOI: 10.1038/Nbt1137  0.96
2005 Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM. Global gene expression profiling of circulating tumor cells. Cancer Research. 65: 4993-7. PMID 15958538 DOI: 10.1158/0008-5472.Can-04-4330  0.96
2005 Weiner LM, Carter P. Tunable antibodies. Nature Biotechnology. 23: 556-7. PMID 15877072 DOI: 10.1038/nbt0505-556  0.96
2005 Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4330-7. PMID 15781882 DOI: 10.1200/Jco.2005.05.017  0.96
2005 Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 4: 351-60. PMID 15767544 DOI: 10.1158/1535-7163.Mct-04-0269  0.96
2004 Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. The Journal of Biological Chemistry. 279: 53907-14. PMID 15471859 DOI: 10.1074/Jbc.M407888200  0.96
2004 Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Research. 64: 6200-6. PMID 15342405 DOI: 10.1158/0008-5472.Can-03-2382  0.96
2004 Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2122-32. PMID 15169798 DOI: 10.1200/Jco.2004.08.083  0.96
2004 Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. International Journal of Radiation Oncology, Biology, Physics. 58: 984-90. PMID 14967460 DOI: 10.1016/J.Ijrobp.2003.09.098  0.96
2004 Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 602-9. PMID 14966084 DOI: 10.1200/Jco.2004.12.034  0.96
2004 Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 53: 513-8. PMID 14760509 DOI: 10.1007/S00280-004-0764-7  0.96
2004 Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy Drug Development Research. 61: 172-187. DOI: 10.1002/Ddr.10345  0.96
2003 Goldberg M, Farma J, Lampert C, Colarusso P, Coia L, Frucht H, Goosenberg E, Beard M, Weiner LM. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report. The Journal of Thoracic and Cardiovascular Surgery. 126: 1168-73. PMID 14566264 DOI: 10.1016/S0022-5223(03)00977-2  0.96
2003 Cheng JD, Weiner LM. Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1590-5. PMID 12738710  0.96
2003 Weiner LM, Carter P. The rollercoaster ride to anti-cancer antibodies. Nature Biotechnology. 21: 510-1. PMID 12721576 DOI: 10.1038/Nbt0503-510  0.96
2003 Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1301-6. PMID 12663718 DOI: 10.1200/JCO.2003.08.040  0.96
2003 von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annual Review of Medicine. 54: 343-69. PMID 12525678 DOI: 10.1146/Annurev.Med.54.101601.152442  0.96
2002 Lewis NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemotherapy and Pharmacology. 50: 257-65. PMID 12357298 DOI: 10.1007/S00280-002-0500-0  0.96
2002 Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Research. 62: 4767-72. PMID 12183436  0.96
2002 Weiner LM. Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control cancer. Oncology (Williston Park, N.Y.). 16: 7-9. PMID 11829282  0.96
2001 McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. Journal of Immunology (Baltimore, Md. : 1950). 166: 6112-7. PMID 11342630 DOI: 10.4049/Jimmunol.166.10.6112  0.96
2001 O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 2413-21. PMID 11331320 DOI: 10.1200/Jco.2001.19.9.2413  0.96
2001 Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. Journal of Immunological Methods. 251: 123-35. PMID 11292488 DOI: 10.1016/S0022-1759(00)00290-8  0.96
2001 Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biotherapy & Radiopharmaceuticals. 16: 9-11. PMID 11279802 DOI: 10.1089/108497801750095925  0.96
2001 Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). American Journal of Clinical Oncology. 24: 43-6. PMID 11232948 DOI: 10.1097/00000421-200102000-00007  0.96
2001 Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. Journal of Immunological Methods. 248: 1-6. PMID 11223064 DOI: 10.1016/S0022-1759(00)00338-0  0.96
2001 Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1183-94. PMID 11181685 DOI: 10.1200/Jco.2001.19.4.1183  0.96
2000 Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene. 19: 6144-51. PMID 11156528 DOI: 10.1038/Sj.Onc.1204000  0.96
2000 Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Seminars in Oncology Nursing. 16: 2-12. PMID 11151455 DOI: 10.1053/Sonu.2000.19775  0.96
2000 Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules Nuclear Medicine and Biology. 27: 339-346. PMID 10938467 DOI: 10.1016/S0969-8051(00)00103-7  0.96
2000 Weiner LM. Bispecific antibodies in cancer therapy Cancer Journal. 6: S265-S271. PMID 10874497 DOI: 10.1016/S0952-7915(99)00015-1  0.96
1999 Amoroso AR, Alpaugh RK, Barth MW, McCall AM, Weiner LM. Production and characterization of mice transgenic for the A and B isoforms of human FcgammaRIII. Cancer Immunology, Immunotherapy : Cii. 48: 443-55. PMID 10550549 DOI: 10.1007/s002620050621  0.96
1999 McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis Molecular Immunology. 36: 433-445. PMID 10449096 DOI: 10.1016/S0161-5890(99)00057-7  0.96
1998 Alpaugh RK, Von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon Medical Oncology. 15: 191-198. PMID 9819796 DOI: 10.1007/Bf02821938  0.96
1998 Keller SM, Ryan LM, Coia LR, Dang P, Vaught DJ, Diggs C, Weiner LM, Benson AB. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer. 83: 1908-16. PMID 9806648 DOI: 10.1002/(Sici)1097-0142(19981101)83:9<1908::Aid-Cncr5>3.0.Co;2-6  0.96
1998 Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer International Journal of Radiation Oncology Biology Physics. 42: 43-50. PMID 9747818 DOI: 10.1016/S0360-3016(98)00172-2  0.96
1998 McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM. Characterization of anti-mouse FcγRII single-chain Fv fragments derived from human phage display libraries Immunotechnology. 4: 71-87. PMID 9661816 DOI: 10.1016/S1380-2933(98)00006-2  0.96
1998 Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu British Journal of Cancer. 77: 1405-1412. PMID 9652755 DOI: 10.1038/bjc.1998.233  0.96
1998 Alpaugh RK, Weiner LM, Persson R, Persson B. Overview of clinical trials employing antibody-targeted superantigens Advanced Drug Delivery Reviews. 31: 143-152. DOI: 10.1016/S0169-409X(97)00098-7  0.96
1997 Weiner LM, Alpaugh RK, Von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins Cancer Immunology Immunotherapy. 45: 190-192. PMID 9435871 DOI: 10.1007/S002620050430  0.96
1997 Weiner LM. Biological therapies for gastrointestinal cancers Current Opinion in Oncology. 9: 373-379. PMID 9251888 DOI: 10.1097/00001622-199709040-00011  0.96
1997 Clark JI, Alpaugh RK, Von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment Cancer Immunology Immunotherapy. 44: 265-272. PMID 9247561 DOI: 10.1007/S002620050382  0.96
1997 Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1994-2007. PMID 9164211 DOI: 10.1200/Jco.1997.15.5.1994  0.96
1996 Von Mehren M, Weiner LM. Monoclonal antibody-based therapy Current Opinion in Oncology. 8: 493-498. PMID 8971469 DOI: 10.1097/00001622-199611000-00009  0.96
1996 Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site Journal of Molecular Biology. 263: 551-567. PMID 8918938 DOI: 10.1006/Jmbi.1996.0598  0.96
1996 Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Cancer Immunology, Immunotherapy : Cii. 42: 141-50. PMID 8640842 DOI: 10.1007/S002620050264  0.96
1996 Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection Journal of Molecular Biology. 255: 28-43. PMID 8568873 DOI: 10.1006/Jmbi.1996.0004  0.96
1995 Schier R, Marks JD, Wolf EJ, Apelld G, Won C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library Immunotechnology. 1: 73-81. PMID 9373335 DOI: 10.1016/1380-2933(95)00007-0  0.96
1995 Haas NB, Schilder RJ, Nash S, Weiner LM, Catalano RC, Ozols RF, O'Dwyer PJ. A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer Investigational New Drugs. 13: 229-233. PMID 8729951 DOI: 10.1007/Bf00873805  0.96
1995 Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting C-erbB-2 and FcγRIII Journal of Hematotherapy. 4: 453-456. PMID 8581384 DOI: 10.1089/Scd.1.1995.4.453  0.96
1995 Langer CJ, Catalano R, Weiner LM, Scher R, Bagchi P, Saren B, Comis RL. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (m-VAC) in advanced, measurable breast carcinoma Cancer Investigation. 13: 150-159. PMID 7874568 DOI: 10.3109/07357909509011684  0.96
1995 Algan O, Coia LR, Keller SM, Engstrom PF, Weiner LM, Schultheiss TE, Hanks GE. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies. International Journal of Radiation Oncology, Biology, Physics. 32: 753-61. PMID 7790262 DOI: 10.1016/0360-3016(94)00592-9  0.96
1995 George AJT, Jamar F, Tai MS, Heelan BT, Adams GP, Mccartney JE, Houston LL, Weiner LM, Oppermann H, Michael Peters A, Huston JS. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide Proceedings of the National Academy of Sciences of the United States of America. 92: 8358-8362. PMID 7667295 DOI: 10.1073/pnas.92.18.8358  0.96
1995 Krigel RL, Padavic-Shaller K, Toomey C, Comis RL, Weiner LM. Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2 Journal of Immunotherapy With Emphasis On Tumor Immunology. 17: 161-170. PMID 7613642 DOI: 10.1097/00002371-199504000-00005  0.96
1995 Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Tai MS, Huston JS, Stafford WF, Bookman MA, Houston LL, Weiner LM. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration Cancer Immunology Immunotherapy. 40: 299-306. PMID 7600561 DOI: 10.1007/Bf01519629  0.96
1995 Adams GP, Weiner LM. Intracellular Single-Chain Fv Antibodies-A Knockout Punch for Neoplastic Cells? Gynecologic Oncology. 59: 6-7. PMID 7557617 DOI: 10.1006/Gyno.1995.1259  0.96
1995 Clark JI, Weiner LM. Biologic treatment of human cancer Current Problems in Cancer. 19: 185-262. PMID 7489640 DOI: 10.1016/S0147-0272(06)80005-X  0.96
1995 Mccartney JE, Tai MS, Hudziak RM, Adams GP, Weiner LM, Jin D, Stafford WF, Liu S, Bookman MA, Laminet AA, Fand I, Houston LL, Oppermann H, Huston JS. Engineering disulfide-linked single-chain fv dimers [(sfv')2] with improved solution and targeting properties: Anti-digoxin 26-10 (sfv')2 and anti-c-erbb-2 741f8 (sfv')2 made by protein folding and bonded through c-terminal cysteinyl peptides Protein Engineering, Design and Selection. 8: 301-314. PMID 7479692 DOI: 10.1093/Protein/8.3.301  0.96
1994 Shpitz B, Chambers CA, Singhal AB, Hozumi N, Fernandes BJ, Roifman CM, Weiner LM, Roder JC, Gallinger S. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. Journal of Immunological Methods. 169: 1-15. PMID 7907638 DOI: 10.1016/0022-1759(94)90119-8  0.96
1994 Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer Investigational New Drugs. 12: 319-321. PMID 7775133 DOI: 10.1007/Bf00873047  0.96
1994 Huston JS, Adams GP, McCartney JE, Tai MS, Hudziak RM, Oppermann H, Stafford WF, Liu S, Fand I, Apell G, Laminet A, Bookman MA, Houston LL, Weiner LM. Tumor targeting in a murine tumor xenograft model with the (sFv′)2 divalent form of anti-c-erbB-2 single-chain Fv Cell Biophysics. 24: 267-278. PMID 7736532 DOI: 10.1007/BF02789238  0.96
1993 Weiner LM, Hudes GR, Kitson J, Walczak J, Watts P, Litwin S, O'Dwyer PJ. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen. Cancer Immunology, Immunotherapy : Cii. 36: 185-90. PMID 8439979 DOI: 10.1007/Bf01741090  0.96
1992 de Palazzo IG, Kitson J, Gercel-Taylor C, Adams S, Weiner LM. Bispecific monoclonal antibody regulation of Fc gamma RIII-directed tumor cytotoxicity by large granular lymphocytes. Cellular Immunology. 142: 338-47. PMID 1535829 DOI: 10.1016/0008-8749(92)90295-Z  0.96
1990 O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1497-503. PMID 2391557 DOI: 10.1200/Jco.1990.8.9.1497  0.96
Show low-probability matches.